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The impact and prevalence of antimicrobial drug
resistance in rural community healthcare settings is uncer-
tain. Prospective surveillance in 51 rural hospitals in Idaho
and Utah examined the epidemiologic features of clinical
cases of methicillin-resistant Staphylococcus aureus
(MRSA) and vancomycin-resistant enterococci (VRE).
Thirty-two cases of VRE were reported; for 6, the patient
had no prior healthcare exposure or coexisting condition.
Among the 724 MRSA cases available for evaluation, 405
(56%) were healthcare-associated (HA-MRSA), and 319
(44%) were community-associated (CA-MRSA). The char-
acteristics of HA-MRSA and CA-MRSA patients with coex-
isting factors were similar, which suggests community
transmission of healthcare strains. CA-MRSA cases with-
out coexisting factors, however, demonstrated features
previously reported for community strains. MRSAinfections
were substantially more frequent than VRE in rural commu-
nities in the western United States. Based on epidemiolog-
ic criteria, a large proportion of MRSA cases were
community-associated. CA-MRSA rates were predictive of
institutional MRSA rates. 
A
ntimicrobial resistance is steadily rising among bacte-
rial pathogens associated with both community- and
healthcare-associated infections (1,2). Among the most
important of these pathogens are vancomycin-resistant
enterococci (VRE) and methicillin-resistant Staphylo-
coccus aureus (MRSA) (3). Risk factors for VRE acquisi-
tion include chronic dialysis, multiple and prolonged hos-
pitalizations, main admitting diagnosis, coexisting factors
(diabetes mellitus, organ transplant, or hepatobiliary dis-
ease), previous infection or colonization with MRSA or
Clostridium difficile, and prior treatment with antimicro-
bial agents (4–6). Most acquisition of VRE in the United
States has occurred in the hospital or intensive care setting
(4,7–9). 
Risk for colonization or infection with S. aureus is
highest in patients with diabetes mellitus, intravenous drug
users, patients undergoing hemodialysis, surgical patients,
and patients with AIDS (10). Additional patient risk factors
for nosocomial MRSA infections, when compared to
methicillin-susceptible S. aureus, include increased num-
ber of coexisting factors; increased length of hospital stay;
exposure to antimicrobial drug agents, especially fluoro-
quinolones; enteral feedings; and surgery (11). In the past
few years, however, reports of patients with serious MRSA
infections who had no known risk factors or exposure to
healthcare settings have been increasing (12–20). The dis-
tinctive properties of community-associated (CA) MRSA
strains compared to nosocomial strains include a much
more susceptible antimicrobial phenotype (due to the pres-
ence of a much smaller staphylococcal cassette chromo-
some [SCC] mecA [type IV]) (21) and the presence of
different exotoxin gene profiles, including Panton-
Valentine leukocidin (17,22,23). Patients tend to be
younger and have skin and soft tissue infections or other
necrotizing infections (17,21). Hospital-acquired (HA)-
MRSAtypically have a much larger SCCmecA (types I, II,
and III) with a much more resistant antimicrobial pheno-
type (12,24). 
The epidemiology of MRSA and VRE transmission
may be different in the rural setting than that reported for
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substantially less in rural community hospitals than terti-
ary care facilities. Some of the reports of CA-MRSAinfec-
tions included patients from rural communities, often
native North American populations (15,16,19,23,25–28).
Alarge study of community MRSAinfection examined the
characteristics of MRSA infections predominantly report-
ed from urban and suburban regional laboratories but rep-
resenting urban, suburban, and rural populations; overall,
12% of MRSA infections were community-associated by
epidemiologic criteria (17). 
To address the extent to which nosocomial MRSA and
VRE are substantive problems in rural hospitals, we con-
ducted a prospective study in rural Utah and Idaho.
Epidemiologic and clinical data on VRE and MRSA clini-
cal cases were collected during a 15-month period in 51
rural communities. The hospitals participating in this epi-
demiologic study had been surveyed about their infection
control practices in 2000 (29). All had policies in place to
institute contact isolation for patients with clinically recog-
nized MRSA and VRE infection. However, none had per-
formed active surveillance cultures to detect patients
needing isolation.
Methods
Participating Hospitals and Study Population
Fifty-one rural hospitals in Idaho and Utah were
recruited to participate in a surveillance project for antimi-
crobial drug resistance funded by the Centers for Disease
Control and Prevention (CDC). The participating institu-
tions represented 89% of the total number of rural hospi-
tals in the 2 states. 
All hospitals except 2 met the Office of Management
and Budget definition of rural location (30). Based on this
definition, a rural county was considered any county that
did not have a metropolitan center with a population
exceeding 50,000 persons. Hospitals within such counties
were considered to meet this rural definition. Among the 2
participating hospitals not meeting this definition, 1 hospi-
tal was in an isolated county slightly exceeding the 50,000
metropolitan population limit but was considered to serve
a primarily rural population. The second was a small hos-
pital (50 beds) located within but at the border of an urban
county. 
Surveillance System
Clinical cases of VRE and MRSAidentified by the clin-
ical laboratories of participating hospitals were reported to
the respective infection control practitioners, who com-
piled demographic, medical history, and other epidemio-
logically relevant data on each case. Individual level race
and ethnicity were not captured. 
In some cases, the microbiology staff contributed to
data collection. The primary source of information was the
patient’s medical record. In most cases direct confirmation
of healthcare exposure through patient or family interview
was not possible. These data were recorded on a standard-
ized data collection form and submitted on a regular, usu-
ally monthly, schedule. Data evaluated in this analysis
were collected from October 1, 2002, to December 31,
2003. All data collected and analyzed were for this 15-
month period, except for incidence rate calculations,
which were for calendar year 2003, as described below.
The following approaches were used to improve the valid-
ity of the data: 1) a data dictionary and operations manual
were created with explicit instructions for completion of
the data collection forms; 2) the data collection protocol
was discussed during conference calls along with frequent
one-on-one communication; and 3) anomalous data in the
data reports were routinely searched for and corrected. 
Epidemiologic Definitions 
Definitions used in this study focused on the location of
the patient at the time of initial culture and the presence or
absence of exposure to the healthcare environment. The
emphasis, therefore, is on healthcare or community associ-
ation rather than definitive identification of the site of
acquisition. These definitions are consistent with those of
CDC and others (16–18,20). 
Healthcare-associated VRE (HA-VRE) 
or MRSA (HA-MRSA)
This category included VRE or MRSA cultured from
patients  >48 hours after hospital admission, or while a
patient of another hospital, resident of a long-term care
facility, or transitional care unit. Also included in this cat-
egory were infected patients with history of prior hospital-
ization or outpatient surgery, prior residence in a long-term
care facility or transitional care unit, or prior care from
home health agency or with documented indwelling
catheters. This group also included patients with a postop-
erative wound infection, even if the surgery was performed
as an outpatient. Patients identified with any of the above
healthcare exposures were included in this category; the
period from healthcare exposure to inclusion was general-
ly 6 months. Patients known to have previous VRE or
MRSA infections or positive cultures were excluded from
analysis. 
Community-associated VRE (CA-VRE) 
or MRSA (CA-MRSA)
This category included VRE or MRSA cultured from
patient <48 hours after hospital admission, or as an outpa-
tient. Excluded from this category were patients with pre-
vious history of positive VRE or MRSA culture or
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residence in a long-term care facility or transitional care
unit, or prior home health. 
Coexisting Factors
This category included medical or other factors possi-
bly associated with healthcare exposure (diabetes mellitus,
renal failure, prior antimicrobial drug therapy, and
immunosuppression). Such factors were assessed for all
groups of VRE and MRSA cases.
CA-VRE or CA-MRSA with Coexisting Factors
This category included VRE or MRSA clinical cases
satisfying the definition for community-associated infec-
tion in which the patient had identifiable coexisting
factors. 
CA-VRE or CA-MRSA without Coexisting Factors.
This category included VRE or MRSA case satisfying
the definition for community-associated infection in which
the patient had no identifiable coexisting factors. 
Incidence Rates
The incidence of CA- and HA-VRE and MRSA were
calculated for each hospital reporting positive cultures
from January 1, 2003, to December 31, 2003. Individual
institutions were excluded from this analysis if the respec-
tive hospital infection control and microbiology staff could
not verbally attest to the completeness of reporting after
the study ended, based on a retrospective review of all
cases during the study period. Thus, hospitals with partial
or incomplete reporting of all cases were not included in
the incidence rate calculations or Poisson regression
model. The described hospital located at the border of the
urban county was also excluded from the incident rate cal-
culations. The denominator for healthcare-associated cases
was the total inpatient census for 2003, including long-
term care facility census if a hospital had such an attached
facility. These data were obtained from published hospital
statistics (31) or by direct communication with hospital
staff. The denominator for community-associated infec-
tions was the most recent estimated county population data
derived from the 2000 census in Idaho (Idaho Department
of Health, http://www2.state.id.us/dhw/vital_stats/health_
district_report.pdf) and Utah (Utah Department of Health,
http://health.utah.gov/vitalrecords/pub_vs/ia02/02bx.pdf).
In both cases, the incidence rates were expressed as the
number of hospital cases per 10,000 patient-days or num-
ber of community cases per 10,000 person-years, based on
county population. Incidence rates for CA-MRSA were
also calculated by using the community population size as
the denominator. For comparison, MRSA incidence rates
for CDC National Nosocomial Infections Surveillance
(NNIS) hospitals during 2003 were obtained (T. Horan and
J. Edwards, pers. comm.).
Susceptibility Testing
Antimicrobial susceptibility results, collected retro-
spectively, were not available for all MRSA cases.
Available data were aggregated and compared among the
different groups of MRSA patients. Specifically, clinical
and epidemiologic characteristics of MRSA cases for
which the infecting organisms were resistant to both clin-
damycin and ciprofloxacin (“resistant group”) and MRSA
cases for which the infecting organisms were sensitive to
both clindamycin and ciprofloxacin (“susceptible group”)
were compared. Phenotypic susceptibility to these 2
antimicrobial agents in MRSA is most often associated
with community acquisition (17,24).  
Data Analysis
All data were entered into an Access (Microsoft
Corporation, Redmond, WA, USA) relational database for
analysis. Proportions of total cases meeting specific epi-
demiologic criteria were calculated, and characteristics of
each category were compared by using Fisher exact test-
ing. Hospital bed size, census data, and age for MRSA
patients were available for most but not all entries. Census
data and ages of patients in each category were compared
with Kruskal-Wallis equality of populations rank test. The
relationship of community MRSA rates and other covari-
ates on the hospital MRSA rates were modeled by using
random effects Poisson regression. In this model, each spe-
cific hospital was considered a unit and was treated as a
random effect; its MRSA cases were assumed to be corre-
lated. That is, the hospitals were considered to be a random
sample of all rural Utah and Idaho hospitals. This assump-
tion permitted inferences to be made to this target popula-
tion, rather than limiting inferences to only those hospitals
included in the model. Continuous predictor variables
were converted to ordered categoric variables and includ-
ed in the models as tertiles, quartiles, or quintiles to verify
that risk was “linearly” increasing. Multivariable models
were fitted by using backwards stepwise variable selec-
tion. All statistical testing was performed with STATA,
version 8 (Stata Corporation, College Station, TX, USA).
All statistical analyses were 2-sided and significance was
set at p<0.05.
Results
Case Ascertainment
A total of 34 unique VRE and 799 unique MRSA cases
were reported by participating rural healthcare institutions
in Idaho and Utah from October 1, 2002, to December 31,
2003. Twenty-six of 51 institutions reported >1 MRSA or
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ers or microbiology staff from 28 institutions confirmed
that reporting was complete; 9 of the 28 institutions with
confirmed complete reporting had no MRSAcases, and 23
of the 28 institutions had no VRE cases during the interval.
The 22 institutions that did not attest to complete reporting
contributed 17 MRSA and 2 VRE cases to the descriptive
case series analysis but were removed from the incidence
rate analysis. The average bed size of institutions with
complete reporting was greater than the average bed size
of institutions that did not attest to complete reporting (53
beds vs. 29 beds, p = 0.03).
Two VRE (6%) and 75 MRSA(8%) cases were exclud-
ed from the case-series analysis because of incomplete
data. Of the 32 VRE cases with complete data, criteria for
HA-VRE infection and CA-VRE infection were met by 25
(78%) and 7 (22%), respectively. Of the remaining 724
MRSA cases, 405 (56%) were HA-MRSA infection and
44% were CA-MRSA infection. Among the CA-MRSA
cases, 79 (25%) were from patients with known coexisting
factors, and 240 (75%) came from patients without any
such factors reported (Table 1). 
Characteristics of VRE and MRSA Clinical Cases
Eight institutions reported at least 1 VRE case. The
major healthcare location of patients with HA-VRE was
the transitional care unit (12/32, 38%); other locations are
outlined in Table 1. Six patients (19%) had no reported risk
factors or known exposure to the healthcare setting. The
most common clinical source of VRE isolates was urine
(15/32, 47%). The major location for patients at the time of
MRSA culture was the community (391/724, 54%) with
the long-term care facility (147/724, 20%) representing the
most common healthcare location (Table 1). The most
common clinical source of MRSA cultures was skin and
soft tissue (400/724, 55%).
The clinical sites of infection for all MRSA cases were
compared (Table 2). Comparison of clinical sources for
MRSA infection between groups of HA-MRSA and CA-
MRSA patients with coexisting factors showed no signifi-
cant differences (data not shown). Patients in the
CA-MRSAgroup without coexisting factors, however, had
the highest proportion of skin/soft tissue infections
(156/240, 65%, p<0.0001). Patients in this group were also
much younger (mean age 41.5 years, n = 178) than the
RESEARCH
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n = 66) (p = 0.0001); the proportion of patients <20 years
of age in this group was 24% (43/178) compared to 2%
(6/351) and 8% (5/66) in the other 2 groups (p<0.0001).
Among hospitals with complete reporting, the fraction of
MRSAcases that were CA-MRSA(with and without coex-
isting factors) was slightly higher in smaller hospitals com-
pared to larger hospitals, but this difference was not
significant (48% if bed size <40 and 41% if bed size >40,
p = 0.323). 
Susceptibility to antimicrobial agents was compared
among these 3 epidemiologic groups of MRSA infections
(Table 3). Susceptibility to 3 key non-β-lactam antimicro-
bial agents (erythromycin, clindamycin, and ciprofloxacin)
was significantly higher in the group of CA-MRSA
patients without coexisting factors than in the other 2
groups. No statistical difference in the susceptibility to
erythromycin, clindamycin, or ciprofloxacin existed
between HA-MRSA and CA-MRSA groups with coexist-
ing factors (data not shown).  
MRSA cases in which the isolate was resistant to both
clindamycin and ciprofloxacin (n = 142) were compared to
cases in which both antimicrobial agents were susceptible
(n = 32) (Table 4). The proportion of patients with skin/soft
tissue infections in the susceptible group (81% vs. 52%, p
= 0.003) increased significantly. Most of the cases in the
susceptible group were community-associated (75% vs.
27%, p<0.0001), and the mean age of the susceptible
group was significantly lower (32 vs. 69, p = 0.0001). 
Comparison of MRSA and VRE Incidence Rates
Incidence rates of VRE and MRSA infections, particu-
larly of HA-MRSA, varied substantially across institutions
(Figure). Rates of CA-MRSAcorrelated strongly with HA-
MRSA rates, regardless of whether CA-MRSA rates were
denominated by community or county population size
(Table 5). The rate of HA-MRSAin hospitals belonging to
the third quintile of CA-MRSA rates was 11-fold higher
than in hospitals with no CA-MRSA (first and second
quintiles). The rate of HA-MRSAin hospitals belonging to
the fourth and fifth quintiles of CA-MRSA rates was >30-
fold higher than in hospitals with no CA-MRSA. This
association was independent of hospital bed size. 
MRSAincidence was also examined in relation to prox-
imity to Native American reservations. HA-MRSA and
CA-MRSA incidence rates at the 7 communities that were
in proximity to Native American reservations were compa-
rable to other communities. Only 1 of these 7 had CA-
MRSA rates in the highest quintile.  
Discussion
Much of our current understanding of MRSA and VRE
in rural communities comes from reports of outbreaks or
smaller case series (15,16,19,23,25–28). In this study, epi-
demiologic data on MRSA and VRE cases were collected
from a large number of rural hospitals in Idaho and Utah
during a 15-month period. VRE incidence was low in all
but 3 institutions. The overall incidence of MRSA infec-
tion was substantially greater and varied widely across
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cantly higher in communities classified as having a high
incidence of CA-MRSA. The incidence rates of HA-
MRSA in communities that did report cases were in a
range comparable to reports from hospitals participating in
the CDC NNIS system (HA-MRSA incidence rates from
NNIS hospitals ranged from 12.6 to 19.5 per 10,000
patient days) (T. Horan and J. Edwards, pers. comm.). The
lack of reporting of MRSAand VRE from many rural hos-
pitals suggests that these resistance types may still be
infrequent in some locations. However, confirming this
finding by performing active surveillance cultures to deter-
mine whether the prevalence of carriage is corresponding-
ly rare in communities without clinical cases would be
useful.  
Forty-four percent of the MRSA cases met epidemio-
logic criteria for being community-associated. These cases
were comparable to CA-MRSA cases reported by other
investigators with respect to the infrequency of coexisting
factors, the predominance of skin and soft tissue infection,
and the increased susceptibility to other antimicrobial drug
classes (12–18). Some cases in the CA-MRSAgroup with-
out coexisting factors had a more resistant phenotype,
which suggests that, even in these patients without obvious
risk factors, healthcare exposure to MRSA occurred, or
descendants of hospital strains of MRSAwere available in
the community for transmission. The subset of CA-MRSA
cases with coexisting factors had characteristics similar to
cases meeting the epidemiologic criteria for healthcare
acquisition. Transmission of healthcare-associated strains
in these cases may have occurred during contact in ambu-
latory rather than hospital settings. These hypotheses are
supported by the work of other investigators (18,32–34). In
1 study, molecular analysis of CA-MRSA isolates in a
nonoutbreak setting demonstrated that the hospital was the
main source of community MRSA (33).
We found that the rate of hospital-associated MRSA
was significantly greater in communities classified as hav-
ing a high incidence of CA-MRSA. Several plausible rea-
sons for this association exist. One possibility is that the
sensitivity of laboratory detection and reporting was better
in communities that had increased rates of both CA- and
HA-MRSA. Another potential explanation is that CA- and
HA-MRSA cases are dynamically interdependent (35).
CA-MRSAcases may contribute to nosocomial dissemina-
tion of MRSAwithin hospitals because of increased preva-
lence of MRSAcarriage at the time of admission, followed
by transmission to other hospitalized patients (36,37).
RESEARCH
900 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 11, No. 6, June 2005
Figure. Box plot of incidence rates of methicillin-resistant
Staphylococcus aureus (MRSA) and vancomycin-resistant entero-
coccal (VRE) infections. CA, community-associated; HA, health-
care-associated.Increased HA-MRSAincidence may in turn foster dissem-
ination of MRSA in community populations. 
A smaller but substantial proportion of the VRE cases
(19%) also met criteria for community association, without
other risk factors. VRE transmission from farm animals to
humans has been reported in Europe, and community
transmission has been suggested as a possible but yet
undocumented mechanism in the United States (7,9).
This study has several limitations. Clinical microbiolo-
gy laboratories, particularly those in rural hospitals, may
have difficulty detecting MRSA, VRE, and other resistant
organisms (38–40). We did not directly evaluate proficien-
cy testing in the current study but have examined this issue
in prior investigations. Laboratory practices in rural hospi-
tals in Idaho and Utah were examined by survey in July
2000 (40). Five institutions in the current study that had
inadequate MRSA confirmation procedures according to
the survey conducted in 2000 had rates of HA-MRSA that
were comparable to institutions with adequate procedures
for confirmation of MRSA. In a follow-up study, laborato-
ry proficiency was assessed by distribution of unknown
specimens for blinded testing to a subset of 28 facilities in
Idaho and Utah (K.B. Stevenson et al., unpub. data).
Reporting of interpretative category for MRSA and VRE
was correct in 100% and 61.5% of hospitals, respectively.
These results highlight the potential for problems in micro-
biology proficiency to contribute to either underdetection
or overdetection of resistant organisms. 
Another potential drawback of this study was that orig-
inal records such as hospital charts were not independent-
ly reviewed to assess the reliability of epidemiologic data
collection by local infection control practitioners. Our use
of an explicit data collection protocol and data dictionary
was designed to mitigate this limitation. Similar methods
of medical record review have been used successfully in
other studies of CA-MRSA (15,16). 
This study focused on patients with clinical infection.
Because serial surveillance cultures were not obtained, the
timing or location of VRE or MRSA acquisition could not
be precisely determined. Surveillance cultures also identi-
fy patients with clinically unrecognized carriage of resist-
ant organisms. MRSA isolates were not collected
prospectively during the study period, which limited our
ability to confirm antimicrobial drug–susceptibility pat-
terns and perform molecular analysis. Examining the clon-
al patterns of isolates by pulsed-field gel electrophoresis
and determining the type of SCCmecA would have been
useful for supporting the interpretations of the epidemio-
logic analysis and overcoming the recognized limitations.
Molecular analyses of MRSA isolates that have been
recently collected from these rural communities are
planned.
Finally, the number of persons corresponding to the
source population for CA-MRSA and CA-VRE cases
could not be precisely determined. Therefore, we could not
derive reliable estimates of CA-MRSA and CA-VRE
infection rates for purposes of comparison with rates from
other geographic locations.
In summary, infection control practitioners and clini-
cians working in rural areas are likely to confront problems
of hospital- and community-associated MRSA infection.
In some rural areas, the MRSA incidence approaches or
exceeds what has been reported from larger hospitals in
urban areas. The role of more aggressive prevention strate-
gies, such as active surveillance culturing, in these rural
healthcare settings is still uncertain. Further studies of the
epidemiologic factors that influence MRSA and VRE
transmission and of infection control interventions in rural
communities are needed. 
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